Revance Therapeutics (NASDAQ:RVNC) issued its quarterly earnings results on Sunday. The biopharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.01, MarketWatch Earnings reports. Revance Therapeutics had a negative return on equity of 85.72% and a negative net margin of 5,818.87%.
RVNC stock traded down $0.98 during mid-day trading on Tuesday, reaching $25.98. The company had a trading volume of 62,717 shares, compared to its average volume of 425,713. The company has a market capitalization of $1.73 billion, a PE ratio of -5.70 and a beta of 1.42. The firm has a 50 day moving average of $28.31 and a 200 day moving average of $26.92. Revance Therapeutics has a 12 month low of $11.78 and a 12 month high of $34.62. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.07 and a quick ratio of 7.01.
In other news, insider Aubrey Rankin sold 33,119 shares of Revance Therapeutics stock in a transaction that occurred on Monday, November 30th. The shares were sold at an average price of $23.85, for a total transaction of $789,888.15. Following the completion of the sale, the insider now owns 67,871 shares of the company’s stock, valued at $1,618,723.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.80% of the company’s stock.
RVNC has been the topic of a number of analyst reports. Barclays boosted their price objective on shares of Revance Therapeutics from $35.00 to $38.00 and gave the company an “overweight” rating in a research report on Monday, October 26th. Mizuho upped their price target on shares of Revance Therapeutics from $30.00 to $33.00 and gave the company a “buy” rating in a report on Tuesday. Needham & Company LLC raised their price objective on shares of Revance Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, January 8th. HC Wainwright upped their target price on Revance Therapeutics from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Zacks Investment Research downgraded Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, February 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $32.88.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine.
Featured Story: How is a management fee different from a performance fee?
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.